uniQure N.V.

13.00
3.61 (38.45%)
At close: Apr 17, 2025, 3:59 PM
38.45%
Bid 12.93
Market Cap 703M
Revenue (ttm) 27.12M
Net Income (ttm) -239.56M
EPS (ttm) -4.92
PE Ratio (ttm) -2.64
Forward PE -4.26
Analyst Buy
Ask 13.15
Volume 14,393,563
Avg. Volume (20D) 1,316,293
Open 13.01
Previous Close 9.39
Day's Range 12.54 - 14.16
52-Week Range 3.73 - 19.18
Beta 0.42

About QURE

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phas...

Industry Biotechnology
Sector Healthcare
IPO Date Feb 5, 2014
Employees 209
Stock Exchange NASDAQ
Ticker Symbol QURE
Full Company Profile

Analyst Forecast

According to 10 analyst ratings, the average rating for QURE stock is "Buy." The 12-month stock price forecast is $32, which is an increase of 146.15% from the latest price.

Stock Forecasts

Next Earnings Release

uniQure N.V. is scheduled to release its earnings on May 6, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
1 day ago
+38.45%
uniQure shares are trading higher after the compan... Unlock content with Pro Subscription
3 months ago
-9.75%
UniQure shares are trading lower after the company announced a public offering of 4.41 million shares.